Phase 2 Castleman Disease Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• You have been diagnosed with KSHV-associated Inflammatory Cytokine Syndrome (KICS) or a condition called KSHV-related Multicentric Castleman Disease (KSHV-MCD), confirmed by a specialist laboratory
• You are 18 years of age or older
• You have at least one ongoing symptom linked to your condition, such as a fever lasting at least one week, significant fatigue, digestive problems like nausea or loss of appetite, or breathing-related symptoms like coughing
• You have at least one abnormal blood test result linked to your condition, such as low red blood cell levels, low platelet counts, low protein (albumin) in the blood, or high levels of a marker of inflammation (C-reactive protein)
• Your condition is not currently causing life-threatening or organ-threatening problems
• You are well enough to carry out some daily activities (your doctor can assess this using a standard scale)
• Your liver, kidney, and blood clotting test results fall within acceptable ranges as defined by the trial
• If you have HIV, you are currently on or willing to start an effective HIV treatment that does not include certain medications that could interfere with the trial drug
• If you have chronic hepatitis B, you are already on treatment to keep it under control
• If you have had hepatitis C in the past, you have completed treatment and had no detectable virus for at least 3 months
• If you have previously received treatments like rituximab or similar medicines, you have stopped taking them at least 3 weeks before joining the trial
• If you are taking certain medications that affect how the liver processes drugs, you have stopped taking them for a sufficient period before joining the trial (confirm with trial site)
• If you are able to become pregnant, you agree to use a highly effective form of contraception before, during, and for 30 days after the trial (certain hormonal contraceptives are not suitable — confirm with trial site)
• If you are able to father a child, you also agree to use or ensure your partner uses a highly effective form of contraception before, during, and for 30 days after the trial
• You are able to understand the trial and are willing to sign a consent form

Who may not be able to join:

• You have significant Kaposi Sarcoma affecting internal organs at a moderate or severe level (except for swelling or non-open sores limited to the mouth)
• You have had an allergic reaction to a drug similar to pacritinib (the trial drug)
• You are currently taking certain medications that strongly affect how the liver breaks down drugs (a group called CYP3A4 inhibitors or inducers)
• You have signs of active bleeding, ongoing blood loss, or have had a serious bleeding problem in the past year
• You have had a serious heart-related event in the last 3 months
• You have an abnormal heart rhythm measurement (called a prolonged QTc interval over 480 ms), heart failure, or a history of a specific heart rhythm disorder
• You are currently taking other medications known to affect heart rhythm
• You have had a blood clot, a heart attack, or a positive test for heart muscle damage in the last 6 months
• You have moderate or severe liver disease (confirm with trial site)
• You have been diagnosed with a type of lymphoma called primary effusion lymphoma, or any other lymphoma
• You have another cancer whose history or treatment could interfere with this trial
• You are currently pregnant (a pregnancy test will be done at screening)
• You are currently breastfeeding, as the trial drug may pose a risk to nursing infants
• You have a bacterial, fungal, or mycobacterial infection that is not under control
• You have another serious ongoing illness that would make it difficult to follow the trial requirements

Important: Always verify eligibility with the trial site directly before applying.